From robbie.mcIntyrezg@moeller-profilsysteme.de Wed Oct 5 01:46:10 2005 Return-Path: Received: from mx1.FreeBSD.org (mx1.freebsd.org [216.136.204.125]) by hub.freebsd.org (Postfix) with ESMTP id 6680016A41F for ; Wed, 5 Oct 2005 01:46:10 +0000 (GMT) (envelope-from robbie.mcIntyrezg@moeller-profilsysteme.de) Received: from moireach.freeserve.co.uk (p54AF655A.dip.t-dialin.net [84.175.101.90]) by mx1.FreeBSD.org (Postfix) with SMTP id 7036143D49 for ; Wed, 5 Oct 2005 01:46:01 +0000 (GMT) (envelope-from robbie.mcIntyrezg@moeller-profilsysteme.de) Message-Id: Date: Wed, 05 Oct 2005 02:42:33 +0100 From: "Robbie McIntyre" To: bug-followup@freebsd.org Subject: There's Nothing Like a Hot PenmnySt0ck >Number: 86918 >Category: junk >Synopsis: There's Nothing Like a Hot PenmnySt0ck >Confidential: no >Severity: serious >Priority: medium >Responsible: gnats-admin >State: closed >Quarter: >Keywords: >Date-Required: >Class: sw-bug >Submitter-Id: current-users >Arrival-Date: Wed Oct 05 01:50:25 GMT 2005 >Closed-Date: Wed Oct 05 08:47:12 GMT 2005 >Last-Modified: Wed Oct 05 08:47:12 GMT 2005 >Originator: >Release: >Organization: >Environment: >Description: ATTENTION INVESTING PUBLIC ASCE . PK Recent Trading Range: $.80 - $.90 Expected Trading Range: $1.50 - $2.00 ASCE . PK BELLEVUE, WA. September 14, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research particularly in anti-cancer compounds and for organizational growth. BELLEVUE, WA. September 27th, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett, President and CEO of Ascentia said, .We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the clinical development of therapies for rheumatic diseases. Dr. Mease.s experience in clinical drug discovery along with his respected relationship with drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program.. Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder of Seattle Rheumatology Associates. Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of Washington, Seattle. About Ascentia Biomedical Corporation Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer. Initially, a majority of these products will be secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused on therapies for cancer and diseases of inflammation. Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. These statements do not constitute representations or promises. Rather, these statements express opinions, hopes and desires that may not be based on objective or factual criteria or measurable results. No one should rely on such statements for any purpose except as specifically stated To get taken off the list email NOSTK@Yahoo.com >How-To-Repeat: >Fix: >Release-Note: >Audit-Trail: State-Changed-From-To: open->closed State-Changed-By: linimon State-Changed-When: Wed Oct 5 08:46:44 GMT 2005 State-Changed-Why: and 'nothing' is probably what you stand to gain. http://www.freebsd.org/cgi/query-pr.cgi?pr=86918 >Unformatted: